Other common epigenetic biomarkers in brain tumors such as glioma include O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, which is related to response to temozolomide (TMZ) therapy. This evidence concerns the gene MGMT and central nervous system cancer.